Single-arm, Open-label Clinical Study of SZ011 in the Treatment of Advanced Triple Negative Breast Cancer

Advanced Triple Negative Breast Cancer Clinical Trial

Official title:
Single-arm, Open-label Clinical Study of SZ011 in the Treatment of Advanced Triple Negative Breast Cancer

Status Not yet recruiting

Clinical Trial Summary

This study was a single-center, open-label, investigator-initiated clinical trial (IIT) to observe and investigate the clinical safety and efficacy of SZ011 in the treatment of advanced triple-negative breast cancer.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Advanced Triple Negative Breast Cancer
Breast Neoplasms
Triple Negative Breast Neoplasms

Clinical Trial Details

NCT number	NCT05686720
Study type	Interventional
Source	First Affiliated Hospital of Shantou University Medical College
Contact	Jing Lin, PhD
Phone	13531285809
Email	316603568@qq.com
Status	Not yet recruiting
Phase	Early Phase 1
Start date	February 1, 2023
Completion date	June 1, 2024

View Details

See also
Status	Clinical Trial	Phase
Terminated	`NCT04927884` - A Study of Sacituzumab With Chemoimmunotherapy to Treat Advanced Triple-Negative Breast Cancer After Prior Therapies	Phase 1/Phase 2
Not yet recruiting	`NCT05019690` - Apatinib Combined With Albumin-Bound Paclitaxel for Treatment of Advanced Triple Negative Breast Cancer	Phase 1/Phase 2
Terminated	`NCT03861403` - A Dose Escalation and Expansion Study of TRX518 in Combination With Cyclophosphamide Plus Avelumab in Advanced Solid Tumors	Phase 1
Withdrawn	`NCT02661100` - A Trial of CDX-1401 in Combination With Poly-ICLC and Pembrolizumab, in Previously Treated Advanced Solid Tumor Patients	Phase 1/Phase 2